Infectious Diseases

First-time visits up sharply, study finds.

The World Health Organization recently declared that boosters are not necessary for children and adolescents in good health.

The COVID-19 vaccine protects against disease and severe effects, but can it help reduce the risk of multisystem inflammatory syndrome in children (MIS-C)?

With increased infectivity of Omicron, the Centers for Control and Prevention (CDC) has updated the guidance on the best mask types to use.

An investigation examines whether self-harm, suicide or suicidal ideation in children and adolescents saw an increase during the pandemic, as anticipated by many clinicians.

A global study examines how often severe outcomes occur within 14 days of a positive COVID-19 test occurring in an emergency department (ED).

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

The US Food and Drug Administration (FDA) made multiple changes to the emergency use authorization for the Pfizer/BioNTech vaccine.

The pandemic led to a number of children missing out on needed vaccines. Getting them back on schedule is imperative.

For mothers who have an experience with human papillomavirus (HPV) vaccine preventable outcomes such as a cervical biopsy or cancer, would this history make them more likely to have their child receive this vaccine? It may seem likely, but a new study raises questions about this belief.

An alarming amount of COVID-19 disinformation is prevalent even from physicians.

Experts answer pediatricians’ and parents’ top questions about this COVID-19 strain’s impact on children.

The US Food and Drug Administration (FDA) has extended the emergency use authorization for the Pfizer/BioNTech COVID-19 vaccine to include a booster dose for teenagers aged 16 to 17 years.

The jury is out on whether testing or exposure better explains the unseasonable surge of respiratory syncytial virus.

The US Food and Drug Administration has accepted a Priority Review of the pneumococcal 15-valent conjugate vaccine VAXNEUVANCE™ in children aged 17 years and younger.

The US Food and Drug Administration (FDA) is currently investigating whether the new COVID-19 variant will evade current mitigation strategies and diagnostic tools.

An update from infectious disease expert, Rana F. Hamdy, MD, on the Omicron variant of COVID-19.

Nearly one-third of hospital personnel had still not been vaccinated against COVID-19 by mid-September.

Sometimes Kawasaki disease doesn’t respond to treatment. An investigation looks into whether a second course of standard treatment performed better than treating with infliximab.

The November issue covered a variety of topics on vaccination, which can help clinicians have candid conversations with colleagues, patients, and families.

Surviving a bout of cancer early in life puts children and teenagers at risk of cancers linked to human papillomavirus (HPV). A phase 2 trial examined how effective a 3-dose series was in providing protection.

Contemporary Pediatrics sat down with editor-in-chief Dr. Tina Q. Tan to discuss the authorization of the Pfizer/BioNTech vaccine for use in many children as well as what lies ahead in the vaccine pipeline for the pediatric population.

The National Institutes of Health announced the launch of a long-term study into the long ranging outcomes of recovering from COVID-19 in children, adolescents, and young adults.

Paul Offit, MD, discusses the state of COVID-19 vaccines and children.